Shuming Nie is the Wallace H. Coulter Distinguished Chair Professor in Biomedical Engineering at Emory University and the Georgia Institute of Technology, with joint appointments in chemistry, materials science and engineering, and hematology and oncology. He is the Principal Investigator and Director of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, one of the eight national centers funded by the National Cancer Institute (NIH/NCI). His research interest is broadly in biomolecular engineering and nanotechnology, with a focus on bioconjugated nanoparticles for cancer molecular imaging, molecular profiling, pharmacogenomics, and targeted therapy. His research program is currently supported by three large-scale grants from the National Institutes of Health. During the last 10 years, Professor Nie has published nearly 100 scholarly papers, filed 20 patents/inventions, and has delivered more than 350 invited talks and keynote lectures. In recognition of his work, Professor Nie has received many awards and honors including the Merck Award (2007), Elected Fellow of the American Institute of Biological and Medical Engineering (2006), the Cheung Kong Professorship (The Ministry of Education of China, 2006), the Rank Prize in Opto-electronics (London, UK, 2005), the Georgia Distinguished Cancer Scholar Award (Georgia Cancer Coalition, 2002-2007), the Beckman Young Investigator Award, the National Collegiate Inventors Award, and the NSFC Overseas Young Scholar Award. Dr. Nie serves on the scientific advisory/editorial boards of 5 biotech companies and 6 scientific journals. Professor Nie received his BS degree from Nankai University (China) in 1983, earned his MS and PhD degrees from Northwestern University under the direction of Professor Richard P. Van Duyne (1984-1990), and did postdoctoral research at both Georgia Institute of Technology and Stanford University (1990-1994).

Svjetlana Miocinovic is a board-certified neurologist specializing in Parkinson’s disease, dystonia, tremor and other movement disorders. She graduated from medical school in 2009 at Case Western Reserve University (Cleveland, Ohio) where she also obtained a PhD in biomedical engineering. She completed neurology residency and clinical movement disorders fellowship at University of Texas Southwestern Medical Center (Dallas, Texas). Her post-doctoral training and clinical research fellowship were at the University of California San Francisco Movement Disorder and Neuromodulation Center. In 2016, she joined the Department of Neurology at Emory University (Atlanta, Georgia). Her clinical focus is on using deep brain stimulations (DBS) to treat movement disorders. She also directs an NIH-funded human electrophysiology laboratory and is an investigator with Emory's Udall Parkinson's Disease Research Center of Excellence. The research focus of her laboratory is on electrophysiology of human motor and non-motor circuits, and development of new device-based therapies. 

Many people are familiar with “genetics,” the inheritance of visible traits like eye and hair color. Traits are encoded by a molecular alphabet (A,T,C,G) in the well known double helix structure, DNA. Less well known, but quickly gaining attention, is the network of protein particles that interact with DNA to control the folding of chromosomes and the expression of inherited traits. This process is epi-genetics (epi, EH-pee = upon or above). Our research group uses gene and protein engineering to create new epigenetic machinery that regulates DNA at will. One day synthetic epigenetics may allow us to rationally design new biological systems with predictable, reliable behavior and replace “magic bullet medicine” with “smart medicine.”

We assemble interchangeable protein modules to build synthetic transcription factors that regulate gene activity in human cells. Unlike typical synthetic transcription factors that recognize specific DNA sequences, our Polycomb-based transcription factors (“PcTFs”) are engineered to read chromatin modifications. Thus, a single engineered TF could activate a group of silenced, therapeutic genes in cancer cells. Using strong gene activators could enhance cancer treatment and advance epigenetic medicine.

As synthetic biologists, our goal is to make the folded DNA-protein material, or chromatin (KRO-mah-tin = dark colored material in the nucleus of a fixed and stained cell), easier to design and engineer. Groups of genes often reside in the same compartments, and share the same DNA-protein packaging structures. Therefore, a small artificial change in one packaging protein can reprogram the expression of dozens, and even hundreds of genes. Is this outcome messy and useless, or is it a powerful mode of signal amplification that changes cells in useful ways? To answer this question, our group couples synthetic biology with bioinformatics by interrogating the expression of thousands of genes after we introduce artificial chromatin proteins into cells.

Dr. Rafael Davalos' research interests are in microfluidics for personalized medicine and developing technologies for cancer therapy. He is most recognized for co-inventing Irreversible Electroporation (IRE), a minimally invasive non-thermal surgical technique to treat unresectable tumors near critical structures such as major blood vessels and nerves. The technology has been used to help thousands of patients worldwide with a second-generation version in clinical trials. Davalos has authored 150 peer-reviewed articles and has 47 issued patents (72 h-index, >18,000 citations) and has secured over $37M in research funding with $10M his share. His patents have been licensed to 7 companies. He has been a plenary speaker for several prestigious venues including the International Symposium of the Bioelectrochemistry Society, the World Congress on Electroporation, and the Society of Cryobiology Annual Meeting. 

The Panitch lab research has focused on the extracellular matrix (ECM) and how matrix signals affect tissue regeneration, including nerve regeneration, wound healing and angiogenesis, cartilage and vascular. More recently, the lab has focused on the proteoglycan component of the ECM. Proteoglycans are critical components of tissue function. They influence matrix organization, the viscoelastic properties of the matrix, access of enzymes to the matrix and serve as a protective barrier as in the case of the glycocalyx. Proteoglycans are difficult to synthesize because of the complex post translational modifications and the complexity of carbohydrate chemistry. The Panitch laboratory has demonstrated that proteoglycan function can largely be recapitulated by conjugating short, bioactive peptide sequences to GAGs. The peptide sequences direct the GAG to its target and ensure that it is held in place, similarly to how native proteoglycans function. The lab has used proteoglycan mimetic strategies to develop therapeutics to treat osteoarthritis, improve wound healing, and treat diseased blood vessels.

Saurabh Sinha received his Ph.D. in Computer Science from the University of Washington, Seattle, in 2002, and after post-doctoral work at the Rockefeller University with Eric Siggia, he joined the faculty of the University of Illinois, Urbana-Champaign, in 2005, where he held the positions of Founder Professor in Computer Science and Director of Computational Genomics in the Carl R. Woese Institute for Genomic Biology until 2022. He joined Georgia Institute of Technology in 2022, as Wallace H. Coulter Distinguished Chair in Biomedical Engineering, with joint appointments in Biomedical Engineering and Industrial & Systems Engineering. Sinha’s research is in the area of bioinformatics, with a focus on regulatory genomics and systems biology. Sinha is an NSF CAREER award recipient and has been funded by NIH, NSF and USDA. He co-directed an NIH BD2K Center of Excellence and was a thrust lead in the NSF AI Institute at UIUC. He led the educational program of the Mayo Clinic-University of Illinois Alliance, and co-led data science education for the Carle Illinois College of Medicine. Sinha has served as Program co-Chair of the annual RECOMB Regulatory and Systems Genomics conference and served on the Board of Directors for the International Society for Computational Biology (2018-2021). He was a recipient of the University Scholar award of the University of Illinois, and selected as a Fellow of the AIMBE in 2018.

Sakis Mantalaris is currently Professor in Biomedical Engineering at Georgia Tech & Emory. Prior he was Professor in Chemical Engineering at Imperial College London. His expertise is in modelling of biological systems and bioprocesses with a focus on mammalian cell culture systems, stem cell bioprocessing, and tissue engineering. He has received several awards: the Junior Moulton Award for best paper by the IChemE (2004), Fellow of AIMBE (2012), an ERC Advanced Investigator Award (2013), and the Donald Medal by the IChemE for his contributions to biochemical engineering (2015).